The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases.
Many economic evaluations of HPV vaccination have been published, but most have focused on the prevention of cervical disease as a primary health outcome. The cost-effectiveness of vaccination is likely to be underestimated if not all HPV-associated diseases are taken into account. In this review, we assess the influence of non-cervical HPV-associated diseases on the incremental cost-effectiveness ratio (ICER) of preadolescent HPV vaccination. Areas covered: We systematically searched the literature and identified 18 studies that included non-cervical diseases in the estimates of cost-effectiveness of HPV-vaccination. When taking other HPV-related diseases into account compared to not including such other diseases, the mean ICERs were 2.85 times more favorable for girls only vaccination and 3.89 times for gender neutral vaccination. Expert commentary: Including non-cervical diseases in economic evaluations of HPV vaccination programs makes it more likely that the ICER falls beneath accepted cost-effectiveness thresholds and therefore increases the scope for gender neutral vaccination.
a Center for Nutrition, Prevention and Health Services , National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands.
Anita W M
AW
Suijkerbuijk
b Center for Epidemiology and Surveillance , National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands.|c Department of Pathology , VU University Medical Centre (VUmc) , Amsterdam , The Netherlands.
Robine
R
Donken
b Center for Epidemiology and Surveillance , National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands.
Anna K
AK
Lugnér
a Center for Nutrition, Prevention and Health Services , National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands.|d Julius Center for Health Sciences and Primary Care , University Medical Center Utrecht , Utrecht , The Netherlands.
G Ardine
GA
de Wit
c Department of Pathology , VU University Medical Centre (VUmc) , Amsterdam , The Netherlands.
Chris J L M
CJ
Meijer
b Center for Epidemiology and Surveillance , National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands.
Hester E
HE
de Melker
b Center for Epidemiology and Surveillance , National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands.
Johannes A
JA
Bogaards
D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D006801:Humans; D009369:Neoplasms / Q000191:economics / Q000517:prevention & control / Q000821:virology; D027383:Papillomaviridae / Q000276:immunology; D030361:Papillomavirus Infections / Q000191:economics / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000191:economics* / Q000627:therapeutic use; D014611:Vaccination / Q000191:economics / Q000379:methods
D053918:Papillomavirus Vaccines
Human Papillomavirus; anogenital cancer; cost-effectiveness; economic evaluation; head and neck cancer; polyvalent vaccines; review; vaccination program